Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652470 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Two Treatments for Infants With Hydrocephalus
A Phase 2 study, sponsored by The Hospital for Sick Children.
- Completed
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT00652470: Completed Phase 2 study, sponsored by The Hospital for Sick Children.
NCT00652470 is a Phase 2 study that has completed, run by The Hospital for Sick Children. The registered enrollment target is 182 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652470, a Phase 2 study, has completed, sponsored by The Hospital for Sick Children.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study is to study whether infants with triventricular hydrocephalus (TVH) have a better long-term outcome at 5 years when they are treated with a new procedure, endoscopic third ventriculostomy (ETV), than infants treated with the more traditional treatment, insertion of a cerebrospinal fluid (CSF) shunt.
Interventions
- PROCEDURE Endoscopic Third Ventriculostomy
- PROCEDURE CSF Shunt Insertion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2005-09 |
| Est. Completion | 2018-05-01 |
| Phase | Phase 2 |
What the finished NCT00652470 record still lists
NCT00652470 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (37% higher).
The record links to 0 conditions, and to 2 interventions - of which Endoscopic Third Ventriculostomy is the first listed.
NCT00652470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00652470 about?
NCT00652470 is a clinical study titled "A Study Comparing Two Treatments for Infants With Hydrocephalus". The purpose of this study is to study whether infants with triventricular hydrocephalus (TVH) have a better long-term outcome at 5 years when they are treated with a new procedure, endoscopic third ventriculostomy (ETV), than infants treated with the more traditional treatment, insertion of a cerebr...
What is the current status of trial NCT00652470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2005-09. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT00652470?
The interventions under investigation include: Endoscopic Third Ventriculostomy (PROCEDURE), CSF Shunt Insertion (PROCEDURE).
Who is sponsoring clinical trial NCT00652470?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00652470's enrollment target sits among peer trials
182 363rd of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia